John R. MacDougall

3.4k total citations · 1 hit paper
36 papers, 2.4k citations indexed

About

John R. MacDougall is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, John R. MacDougall has authored 36 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Molecular Biology and 7 papers in Cancer Research. Recurrent topics in John R. MacDougall's work include Peptidase Inhibition and Analysis (8 papers), Protease and Inhibitor Mechanisms (7 papers) and Cell Adhesion Molecules Research (5 papers). John R. MacDougall is often cited by papers focused on Peptidase Inhibition and Analysis (8 papers), Protease and Inhibitor Mechanisms (7 papers) and Cell Adhesion Molecules Research (5 papers). John R. MacDougall collaborates with scholars based in United States, Canada and United Kingdom. John R. MacDougall's co-authors include Lynn M. Matrisian, Robert S. Kerbel, Charles H. Graham, Peeyush K. Lala, Nelson K.S. Khoo, Robert G. Hawley, Teresa S. Hawley, Yulia Lin, Maria Rosa Bani and William G. Stetler‐Stevenson and has published in prestigious journals such as Nature, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

John R. MacDougall

36 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Establishment and Characterization of First Trimester Human Trophoblast Cells with Extended Lifespan

1993 915 citations Charles H. Graham, Teresa S. Hawley et al. Experimental Cell Research profile →

Peers

Countries citing papers authored by John R. MacDougall

Since Specialization

Citations

This map shows the geographic impact of John R. MacDougall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. MacDougall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. MacDougall more than expected).

Fields of papers citing papers by John R. MacDougall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. MacDougall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. MacDougall. The network helps show where John R. MacDougall may publish in the future.

Co-authorship network of co-authors of John R. MacDougall

This figure shows the co-authorship network connecting the top 25 collaborators of John R. MacDougall. A scholar is included among the top collaborators of John R. MacDougall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John R. MacDougall. John R. MacDougall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract 4945: Inhibition of wild-type PI3Kα signaling is required for durable efficacy in PI3Kα mutant cancer cells due to robust re-activation of wild-type PI3Kα signaling 2023 ·Cancer Research ·John R. MacDougall, Mengqi Zhong, Hanne Merritt, (unknown), John S. Bradley, Raymond H. Mak, Neil S. Dhawan, Wei Chen	1
2	Abstract 4946: TOS-358, a first-in-class covalent PI3Kα inhibitor, demonstrates superior efficacy and does not induce significant hyperglycemia at efficacious doses in multiple animal models 2023 ·Cancer Research ·John R. MacDougall, John S. Bradley, Raymond H. Mak, Neil S. Dhawan, Wei Chen	3
3	DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma 2021 ·Journal for ImmunoTherapy of Cancer ·Allison A. Fitzgerald, Shangzi Wang, Veena R. Agarwal, Emily F. Davis-Marcisak, (unknown), Sandra A. Jablonski, Melanie Loth, Elana J. Fertig, John R. MacDougall, Eugene A. Zhukovsky, (unknown), Dimple Bhatia, Vince O’Neill, Louis M. Weiner	53
4	Abstract 6636: Therapy with BXCL701 (B), a DPP8, DPP9, DPPIV and FAP inhibitor, in combination with anti-PD1 antibody (PD1) in a syngeneic murine pancreatic ductal adenocarcinoma (PDAC) model improves treatment outcomes and induces intratumoral NK cell infiltrates and a marked reduction in tumor stromal fibrosis 2020 ·Cancer Research ·Shangzi Wang, Allison A. Fitzgerald, (unknown), (unknown), Louis M. Weiner, John R. MacDougall, Veena R. Agarwal, Vince O’Neill	2
5	Abstract LB-077: Dipeptidyl Peptidase Inhibitor BXCL701 synergizes with an OX40-agonist antibody resulting in synergistic anti-tumor response and survival in an animal model of colorectal cancer by bridging the innate and adaptive arms of the immune system 2019 ·Cancer Research ·Veena R. Agarwal, John R. MacDougall, Dimple Bhatia, (unknown), (unknown), Nirmal Keshava	1
6	An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma 2017 ·Molecular Cancer Therapeutics ·Rhonda C. Kines, Isabella Varsavsky, (unknown), Debaditya Bhattacharya, (unknown), (unknown), Shin J. Kang, Hans E. Grossniklaus, Demetrios G. Vavvas, (unknown), John R. MacDougall, (unknown), John T. Schiller	45
7	Inhibition of Hedgehog Signaling Antagonizes Serous Ovarian Cancer Growth in a Primary Xenograft Model 2011 ·PLoS ONE ·Christopher McCann, Whitfield B. Growdon, (unknown), Michael D. Curley, Anne M. Friel, Jennifer Proctor, (unknown), Igor V. Deyneko, (unknown), Vinod Vathipadiekal, Michael J. Birrer, Darrell R. Borger, Gayatry Mohapatra, Lawrence Zukerberg, Rosemary Foster, John R. MacDougall, Bo R. Rueda	57
8	Hsp90 (Heat Shock Protein 90) Inhibitor Occupancy Is a Direct Determinant of Client Protein Degradation and Tumor Growth Arrest in Vivo 2010 ·Journal of Biological Chemistry ·Bonnie Tillotson, Kelly L. Slocum, (unknown), (unknown), Brian D. Thomas, Kip A. West, John R. MacDougall, Jie Ge, Janid A. Ali, Vito J. Palombella, Emmanuel Normant, Julian Adams, Christian Fritz	37
9	Depilation induced anagen as a model to study hedgehog pathway antagonist IPI-926: Implications for biomarker development 2008 ·Cancer Research ·L. Kerrie, Everton Mandley, (unknown), Christine Pien, John R. MacDougall, Jennifer Hoyt, (unknown), Louis Grenier, Grace Lin, (unknown), Margaret Read, Karen McGovern	1
10	Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB 2007 ·Cancer Chemotherapy and Pharmacology ·Vincent A. Pollack, Enrique Álvarez, (unknown), Michael Torgov, (unknown), Suresh Shenoy, John R. MacDougall, Sharon Arrol, Haihong Zhong, Robert Gerwien, William F. Hahne, Peter D. Senter, (unknown), Henri S. Lichenstein, William J. LaRochelle	58
11	Recombinant Human FIZZ3/Resistin Stimulates Lipolysis in Cultured Human Adipocytes, Mouse Adipose Explants, and Normal Mice 2005 ·Endocrinology ·Tatiana Ort, Anibal A. Arjona, John R. MacDougall, (unknown), M.E. Rothenberg, Frank Wu, Andrew Eisen, Yuan‐Di C. Halvorsen	63
12	Genome-Scale Analysis of Lung Cancer Progression 2004 ·PubMed ·Uriel M. Malyankar, John R. MacDougall	7
13	Construction, Expression, and Characterization of a Baculovirally Expressed Catalytic Domain of Human Matrix Metalloproteinase-9 2001 ·Protein Expression and Purification ·(unknown), John R. MacDougall, Shahram Khademi, Laurence Cooke, Linda A. Guarino, Edgar F. Meyer, Reza Forough	8
14	Matrix metalloproteinase-3–dependent generation of a macrophage chemoattractant in a model of herniated disc resorption 2000 ·Journal of Clinical Investigation ·Hirotaka Haro, Howard C. Crawford, Barbara Fingleton, John R. MacDougall, Kenichi Shinomiya, Dan M. Spengler, Lynn M. Matrisian	159
15	‘Proteolytic switching’: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression 1999 ·British Journal of Cancer ·John R. MacDougall, Maria Rosa Bani, Yulia Lin, Ruth J. Muschel, Robert S. Kerbel	51
16	Constitutive Production of 92-kDa Gelatinase B Can Be Suppressed by Alterations in Cell Shape 1995 ·Experimental Cell Research ·John R. MacDougall, Robert S. Kerbel	23
17	Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis 1995 ·Cancer and Metastasis Reviews ·John R. MacDougall, Lynn M. Matrisian	366
18	Resistance of Malignant Trophoblast Cells to both the Anti-proliferative and Anti-invasive Effects of Transforming Growth Factor-β 1994 ·Experimental Cell Research ·Charles H. Graham, (unknown), John R. MacDougall, Robert S. Kerbel, William G. Stetler‐Stevenson, Peeyush K. Lala	146
19	Establishment and Characterization of First Trimester Human Trophoblast Cells with Extended Lifespan breakdown → 1993 ·Experimental Cell Research ·Charles H. Graham, Teresa S. Hawley, Robert G. Hawley, John R. MacDougall, Robert S. Kerbel, Nelson K.S. Khoo, Peeyush K. Lala	915
20	Demonstration of a splenic cytotoxic effector cell in mice of genotype SCID/SCID.BG/BG 1990 ·Cellular Immunology ·John R. MacDougall, B. Anne Croy, Christine Chapeau, David A. Clark	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact